Background
Screening for anal premalignant lesions related to human papillomavirus (HPV) is now recommended in France (National Society of Coloproctology 2022, French HIV Guidelines 2024) for men ≥ 30 years living with HIV who have sex with men, and for women ≥ 30 years living with HIV with a history of high-grade lesions or vulvar/cervical cancer. The management algorithm relies on HPV16 detection. Our objective was to provide clinical, virological, cytological, and histological feedback from Bordeaux University Hospital following the implementation of these recommendations at the end of 2023.
Methods
Anal swabs were collected by self-sampling during HIV outpatient visits (Rovers® Anex® Brush, Preservcyt medium (Hologic®)). HPV16 detection was performed using the COBAS HPV ROCHE® assay. When positive, reflex cytology was performed. In the presence of abnormal cells, patients were referred to a proctologist for high-resolution anoscopy (HRA), with or without anal biopsy.
Results
Among 385 anal swabs (370 men, 15 women), 36 results were invalid (9.2%). Among 349 valid swabs, HPV16 was positive in 80 (22,9%): 78 men and 2 women.
Among 78 HPV 16 positive men the cytology results were: , 9 (11,5%)paucicellular, 22 (28%) showed no abnormal cells, and 47 (60%) had cytologic abnormalities: 9 (11.5%) ASC-US, 29 (37%) LSIL, 6 (8%) ASC-H, and 3 (4%) HSIL. In women, 1 ASCUS and 1 LSIL both waiting for their HRA.
Anal biopsy under HRA was performed on an average of 3 months’ time after swabbing, in 19 men (40% of men with cytological abnormalities). Of these, 11 (58%) showed abnormalities: 7 LSIL (37%) and 4 HSIL (21%).
Conclusions
The implementation of the national recommendations in our center highlighted key challenges, including the underrepresentation of women, a high proportion of invalid virological and cytological samples, and limited access to HRA-guided biopsies due to scheduling constraints. However, once the care pathway was established, self-sampling during HIV follow-up visits proved to be a valuable secondary prevention tool, enabling broader patient engagement and improved detection of anal premalignant lesions, particularly among those reluctant to undergo systematic proctology visits.